Literature DB >> 7069588

Morphine pharmacokinetics: GLC assay versus radioimmunoassay.

D R Stanski, L Paalzow, P O Edlund.   

Abstract

The validity of a radioimmunoassay (RIA) for research on the pharmacokinetics of morphine has been questioned because of the possible measurement of cross-reactive metabolites. An RIA using antiserum derived from the 3-O-carboxymethylmorphine hapten was compared with a specific GLC assay in the measurement of plasma morphine concentrations in humans. The ratio of values for morphine concentrations measured using RIA and those measured using GLC was determined. The RIA values resulted in a 27% overestimation of this ratio. This overestimation did not significantly affect the values for terminal elimination half-life, volume of distribution at steady state, or total body clearance that were derived using results from each assay and model-independent pharmacokinetic techniques.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7069588     DOI: 10.1002/jps.2600710313

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

Review 1.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

Review 2.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

3.  Morphine kinetics after diamorphine infusion in premature neonates.

Authors:  D A Barrett; A C Elias-Jones; N Rutter; P N Shaw; S S Davis
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

4.  Cimetidine does not alter morphine disposition in man.

Authors:  P Mojaverian; I L Fedder; P H Vlasses; H H Rotmensch; M L Rocci; B N Swanson; R K Ferguson
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.